Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies
Trial details
- Registry ID
- NCT05054725
- Phase
- Phase 2
The FDA approved Sotorasib (AMG 510) on 28 May 2021.
Drug identity checked against registry records
Also recorded as AMG 510; Lumakras
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard TherapiesNCT05054725 | RVMD | Phase 2 | Completed | 2024-07-03Actual |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2021-05-28Day | Sotorasib | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "NDA214665", "applicant_as_listed_by_fda": "AMGEN INC", "brand_names": ["LUMAKRAS"], "active_ingredients": ["SOTORASIB"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20210528", "matched_on": "drug name equals FDA sole active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |